LeonaBio Announces Series A Warrants Exercisable; Potential $146M

What Happened LeonaBio, Inc. filed an 8-K (Sept 22, 2026) disclosing that warrants issued in a December 2025 private placement (the "Series A Common Warrants") became exercisable on September 18, 2026 and will remain exercisable through October 19, 2026. The Company issued 23,031,494 Series A Common Warrants with an exercise price of $6.35 per share. If all warrants are exercised for cash, the Company would receive approximately $146.2 million.

Key Details

• 23,031,494 Series A Common Warrants issued (December 2025, private placement).
• Exercise price: $6.35 per share.
• Exercisable period: September 18, 2026 through October 19, 2026.
• If exercised in full for cash: ~ $146.2 million in proceeds; proceeds may be reduced or eliminated if holders use a cashless net exercise (e.g., if the Company's resale registration is not effective).

Why It Matters This event creates a near-term window (about one month) when holders can convert warrants into shares, potentially providing the company with a substantial cash infusion if exercised for cash. For investors, the outcomes to watch are (1) whether a resale registration statement is effective (which affects whether exercises are cash or cashless) and (2) the extent to which holders exercise their warrants—both affect LeonaBio’s cash position and share count (dilution) in the short term. The filing also includes standard forward-looking statements and cautions that actual proceeds are uncertain.